Riskpilot← Back to searchSign inGet full accessBIOZEP AS
ASActiveOrg 898229602Gjerdrums Vei 11, 0484 OsloAnnen forskning og annet utviklingsarbeid innen naturvitenskap og teknikk · NACE 72190Est. 20120 employeeswww.biozep.com
Revenue 2022
NOK 0
EBITDA margin
—
+40% vs 2021
Equity ratio
98.9%
Financial strength
Net profit 2022
NOK -135K
+21% vs 2021
| Revenue | NOK 0 | — |
| EBITDA | NOK -54K | +40% |
| Net profit | NOK -135K | +21% |
| Total assets | NOK 730K | -20% |
| Equity | NOK 723K | -16% |
| Employees | 0 | — |
Legal name
BIOZEP AS
Org number
898229602
Legal form
Aksjeselskap
NACE code
72190 · Annen forskning og annet utviklingsarbeid innen naturvitenskap og teknikk
Founded
11. april 2012
Share capital
NOK 62 285 700
Employees
0
VAT registered
No
Audit selected
No
Last report
2022-12-31
Financial year
January – December
Signatory rights
Styrets leder og ett styremedlem i fellesskap.
Company purpose
Utvikling, markedsføring, fremstilling/salg av legemidler og andre produkter som naturlig faller sammen med dette herunder å delta i andre selskaper med lignende virksomhet samt rådgivning.
Address
Gjerdrums Vei 11, 0484 Oslo
Website
www.biozep.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 68 | 32 | 0 | 150 | 621 | 53 | 283 | 214 | 80 | 4 | 0 |
| Staff expenses | −0 | −0 | −0 | −0 | −428 | −983 | −1 591 | −499 | −2 | −0 | 50 |
| EBITDA | −14 | 19 | −14 | −257 | −447 | −2 337 | −3 618 | −809 | −200 | −91 | −54 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 | −14 | −54 | −134 | −97 | −79 | −79 |
| EBIT | −14 | 19 | −14 | −257 | −447 | −2 351 | −3 673 | −942 | −298 | −170 | −134 |
| Net financials | −0 | −1 | 0 | −5 | −6 | 3 | 2 | −3 | 7 | −1 | −1 |
| Profit before tax | −15 | 18 | −14 | −262 | −453 | −2 348 | −3 671 | −945 | −291 | −170 | −135 |
| Tax | −4 | 5 | −0 | −0 | −227 | −346 | −629 | −231 | −0 | −0 | −0 |
| Net profit | −11 | 13 | −14 | −262 | −226 | −2 002 | −3 043 | −714 | −291 | −170 | −135 |
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 191 | 108 | 89 | 262 | 429 | 5 171 | 1 826 | 1 156 | 1 081 | 910 | 730 |
| Equity | 89 | 102 | 88 | 55 | 329 | 5 075 | 2 032 | 1 318 | 1 027 | 857 | 723 |
| Long-term debt | 101 | 0 | 0 | 201 | 250 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 1 | 6 | 1 | 5 | −151 | 96 | −206 | −162 | 54 | 53 | 8 |
| Total debt | 102 | 6 | 1 | 207 | 99 | 96 | −206 | −162 | 54 | 53 | 8 |
EBITDA margin
-5440400.0%
This company
15.8%
Market median
-34433011% vs market
20122022
Equity ratio
98.9%
This company
38.2%
Market median
+159% vs market
20122022
Return on equity
-18.6%
This company
18.4%
Market median
-201% vs market
20122022
Net profit margin
-13453100.0%
This company
8.1%
Market median
-166087754% vs market
20122022
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20122022
Debt / equity
0.01×
This company
0.62×
Market median
+98% vs market
20122022
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Brønnøysundsregistrene · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Brønnøysundsregistrene · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Brønnøysundsregistrene · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Brønnøysundsregistrene · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via Brønnøysundsregistrene · Period 2015-01-01 – 2015-12-31
- Annual report 2014Filed via Brønnøysundsregistrene · Period 2014-01-01 – 2014-12-31
- Annual report 2013Filed via Brønnøysundsregistrene · Period 2013-01-01 – 2013-12-31
- Annual report 2012Filed via Brønnøysundsregistrene · Period 2012-03-21 – 2012-12-31
No data on file.
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2020 | — | — | |
| Chairman | 2020 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Holmeide Holding As | Company | 61.0% | 61.0% | 2022 |
Hefring As | Company | 22.9% | 22.9% | 2022 |
S Nylund Holding As | Company | 9.2% | 9.2% | 2022 |
Keil Consulting As | Company | 2.3% | 2.3% | 2022 |
| Individual | 1.4% | 1.4% | 2022 | |
| Individual | 1.1% | 1.1% | 2022 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Hefring As
BIOZEP AS Board members of BIOZEP AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Robert Keil | Board of Directors | 0 companies |
| Anne Kristin Holmeide | Chairman | 0 companies |